Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors (PRT-BC)
A Single-Arm Pilot Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors
The goal of this study is to evaluate the feasibility, acceptability, and preliminary clinical effects of an oncology-adapted Pain Reprocessing Therapy (PRT) intervention for women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). AIMSS is a common complication of aromatase inhibitor therapy for estrogen receptor-positive breast cancer and is associated with chronic pain, functional impairment, and premature discontinuation of endocrine therapy. The study will evaluate whether a six-session, manualized PRT intervention delivered remotely by trained palliative care therapists is feasible to implement and shows preliminary evidence of improving pain and physical function.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jonathan Song
- 电话号码:734-615-1279
- 邮箱:wmsong@umich.edu
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- History of ductal carcinoma in situ (DCIS) or Stage I-III estrogen receptor-positive breast cancer.
- Post-menopausal prior to starting AI or receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy.
- Currently taking aromatase inhibitor therapy - anastrozole, exemestane, or letrozole - for adjuvant treatment of breast cancer or for chemoprevention.
- Current aromatase inhibitor therapy for at least 3 weeks and no more than 2 years prior to enrollment.
- Diagnosis of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), defined as new or worsening joint pain and/or myalgias since starting aromatase inhibitor therapy,
- Have had at least 3 months of recovery since the last invasive surgery
- Adequate home internet access, defined as reliable access to a private internet connection or cellular data service that supports real time two-way audiovisual telehealth visits using the University of Michigan-approved video conferencing platform on a computer tablet or smartphone. Participants must be able to complete study telehealth visits from a private location.
Exclusion Criteria:
- Evidence of active cancer or progression of disease on most recent imaging, confirmed with the treating oncologist.
- Planned invasive surgery during Day 0-60, that could interfere with study participation, pain assessment, or functional outcomes.
- Concurrent inflammatory arthropathy or autoimmune disorder.
- Patient self-report or EMR documentation of moderate to severe memory impairment or a dementia diagnosis as these would interfere with the ability to understand and remember key elements of the intervention.
- Current participation in cognitive behavioral therapy or other psychological therapy for pain, as concurrent pain-focused psychotherapy could confound interpretation of the effects of the study intervention. If they received psychotherapy in the past, they must be at least 30 days from their last session to enroll.
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment Arm
PRT is a form of psychotherapy that incorporates pain neuroscience education (reframing chronic pain as a predominantly safe signal arising from the brain and nervous system rather than as something that only arises from damaged tissues) with mindfulness meditation and graded exposure strategies. . For this study, PRT has been adapted for the oncology and cancer survivorship context, and includes attention to cancer-related uncertainty, fear of recurrence, medical trauma, treatment-related bodily changes, and concerns about pain as a possible signal of cancer progression. The intervention is manualized and delivered over six sessions. |
All participants will be asked only to participate in six 30-45 min intervention sessions. Participants will need to complete the sessions in the order specified. PRT will be delivered remotely by trained palliative care therapists using a HIPAA compliant secure video conferencing platform. Each session will last approximately 30-45 minutes. The intervention will be delivered in English only. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recruitment - Number
大体时间:11 months of recruitment activity
|
Number of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Recruitment - proportion
大体时间:11 months of recruitment activity
|
Proportion of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Retention - Assessments completed
大体时间:180 days
|
Mean number of post intervention assessments completed per subject; |
180 days
|
|
Retention - Proportion
大体时间:180 days
|
proportion of subjects completing the Day 60 and Day 180 assessments |
180 days
|
|
Intervention Uptake: PRT Sessions count
大体时间:60 days
|
Mean number of PRT sessions attended per subject |
60 days
|
|
Intervention Uptake: proportions of participants
大体时间:60 days
|
proportion completing at least 4 of 6 sessions and proportion completing all 6 sessions. |
60 days
|
|
Representativeness:
大体时间:11 months of enrollment activity
|
The demographic and clinical characteristics of enrolled participants vs. those of potentially eligible patients identified from the University of Michigan Rogel Cancer Center source population during the recruitment period. |
11 months of enrollment activity
|
|
Intervention fidelity.
大体时间:60 days of intervention
|
Intervention fidelity will be assessed through structured session checklists completed by interventionists after each visit, documenting delivery of required PRT components, session duration, and any deviations from the manual. |
60 days of intervention
|
|
Acceptability of PRT intervention
大体时间:after 60 days of intervention
|
Treatment Acceptability and Adherence Scale (TAAS), a 10-item scale assessing perceived acceptability and usefulness of a behavioral intervention.(Milosevic et al., 2015) Scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention). |
after 60 days of intervention
|
|
Participant satisfaction
大体时间:after 60 days of intervention
|
The CSQ-8 yields a total score ranging from 8 to 32, with higher scores indicating greater satisfaction. |
after 60 days of intervention
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pain severity
大体时间:up to 180 days
|
Pain severity will be measured using a 0-10 Numeric Rating Scale (NRS) assessing average pain over the prior 7 days, with anchors of 0 ("no pain") and 10 ("worst pain imaginable") (Jensen et al., 1986). |
up to 180 days
|
|
Change in Pain impact
大体时间:up to 180 days
|
Pain impact will be assessed using the Pain, Enjoyment of Life, and General Activity (PEG) scale, a validated 3-item composite measure of pain severity and pain-related interference (Keller et al., 2004; Krebs et al., 2010). |
up to 180 days
|
|
Pain Interferece
大体时间:up to 180 days
|
Pain interference will be assessed using the PROMIS Pain Interference Short Form 6b, a 6-item measure evaluating the extent to which pain interferes with daily activities, social participation, and enjoyment of life over the past 7 days |
up to 180 days
|
|
Physical Function T-scores
大体时间:up to 180 days
|
Physical function will be measured using the PROMIS Physical Function 4a, a validated 4-item patient-reported measure of physical functioning. Scores will be converted to standardized T-scores, with higher scores indicating better physical function |
up to 180 days
|
合作者和调查者
调查人员
- 首席研究员:Maria Silveira, MD、University of Michigan
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- UMCC 2026.079
- U54AG0923230 (其他赠款/资助编号:National Institutes of Health)
- HUM00292989 (其他标识符:University of Michigan Rogel Cancer Center)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Deidentified patient quantitative data and qualitative transcripts will be provided to a data repository at the University of Colorado which will gather the data on behalf of the National Institute of Aging.
IPD 共享时间框架
within 12 months of last participant completing study
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.